🇺🇸 FDA
Patent

US 11679112

Cancer treatments using combinations of CDK and ERK inhibitors

granted A61KA61K31/4439A61K31/506

Quick answer

US patent 11679112 (Cancer treatments using combinations of CDK and ERK inhibitors) held by Biomed Valley Discoveries, Inc. expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Biomed Valley Discoveries, Inc.
Grant date
Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
50
CPC classes
A61K, A61K31/4439, A61K31/506, A61K31/519, A61K45/06